| Literature DB >> 29868505 |
Syed Z Shah1, Basit Jabbar1,2, Nadeem Ahmed1, Anum Rehman3, Hira Nasir1, Sarooj Nadeem1, Iqra Jabbar4, Zia Ur Rahman1, Shafiq Azam1.
Abstract
In South Asia, Haemaphysalis spinigera tick transmits Kyasanur Forest Disease Virus (KFDV), a flavivirus that causes severe hemorrhagic fever with neurological manifestations such as mental disturbances, severe headache, tremors, and vision deficits in infected human beings with a fatality rate of 3-10%. The disease was first reported in March 1957 from Kyasanur forest of Karnataka (India) from sick and dying monkeys. Since then, between 400 and 500 humans cases per year have been recorded; monkeys and small mammals are common hosts of this virus. KFDV can cause epizootics with high fatality in primates and is a level-4 virus according to the international biosafety rules. The density of tick vectors in a given year correlates with the incidence of human disease. The virus is a positive strand RNA virus and its genome was discovered to code for one polyprotein that is cleaved post-translationally into 3 structural proteins (Capsid protein, Envelope Glycoprotein M and Envelope Glycoprotein E) and 7 non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). KFDV has a high degree of sequence homology with most members of the TBEV serocomplex. Alkhurma virus is a KFDV variant sharing a sequence similarity of 97%. KFDV is classified as a NIAID Category C priority pathogen due to its extreme pathogenicity and lack of US FDA approved vaccines and therapeutics; also, the infectious dose is currently unknown for KFD. In India, formalin-inactivated KFDV vaccine produced in chick embryo fibroblast is being used. Nevertheless, further efforts are required to enhance its long-term efficacy. KFDV remains an understudied virus and there remains a lack of insight into its pathogenesis; moreover, specific treatment to the disease is not available to date. Environmental and climatic factors involved in disseminating Kyasanur Forest Disease are required to be fully explored. There should be a mapping of endemic areas and cross-border veterinary surveillance needs to be developed in high-risk regions. The involvement of both animal and health sector is pivotal for circumscribing the spread of this disease to new areas.Entities:
Keywords: KFDV; animal models; diagnosis; molecular epidemiology; pathogenesis; prevention and control; transmission
Mesh:
Substances:
Year: 2018 PMID: 29868505 PMCID: PMC5954086 DOI: 10.3389/fcimb.2018.00149
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Overview of tick-borne diseases caused by possible causative agents i.e., bacteria (B), viruses (V), and protozoa (P) with reference to organism, vector, host, geographical distribution, symptoms, zoonosis (Z), fatality rate, availability of therapeutics, and vaccination.
| 1 | Relapsing fever | B | Humans, rodents | Spain, Saudi Arabia, Africa, Asia, Canada, Western united States | High fever, flu, headache, muscle pain, rigors, cough, joint pain, rash | + | 1% with treatment, 30–70% without treatment | Penicillin, tetracycline, doxycycline, erythromycin | Not available | Otranto et al., | ||
| 2 | Tularemia | B | Humans, rodents, hares and rabbits | US-Southeast, West, South-central, widespread | Fever, chills, headache, exhaustion, skin ulcer, swollen lymph glands | + | <2% with treatment, 30–60% without treatment | Streptomycin, gentamycin, doxycycline | Live attenuated vaccine is available | Guglielmone et al., | ||
| 3 | Lyme disease or borreliosis | B | Humans, pets, livestock | Eurasia, North America | Fever, arthritis, neuroborreliosis, erythema migrans, cranial nerve palsy, carditis, fatigue, and influenza-like illness | + | 100% | Doxycycline, amoxicillin | Not yet available | Lane et al., | ||
| 4 | Helvetica spotted fever | B | Humans, rodents | Switzerland, Laos, France, Sweden | Red spots, fever, muscle pain, headache, respiratory problems | + | Not documented | Phenoxymethylpenicillin | Not yet available | Parola and Raoult, | ||
| 5 | Ehrlichiosis anaplasmosis/ Human granulocytic ehrlichiosis or HGE | B | Humans, deer, wild and domestic dogs, domestic ruminant, rodents | US-South central, South atlantic | high fever, weakness, headache, fatigue, muscle aches (myalgia), chills | + | <1% | Doxycycline | Not yet available | Charrel et al., | ||
| 6 | STARI (Southern tick-associated rash illness) | B | Humans, dogs, cats | South Central and south eastern United states | Influenza, fatigue, muscle pain, headache | + | Not documented | doxycycline | No vaccine available | Bugrysheva et al., | ||
| 7 | Q fever | B | Goats, sheep and cattle | Worldwide spread | Clay-colored stools, chills or sweats, cough, headache, diarrhea, nausea, chest pain | + | 1–11% | Doxycycline, hydroxychloroquine | Q-Vax, a whole-cell, inactivated vaccine | Sreenivasan et al., | ||
| 8 | Erythema-Migrans or rash | B | Humans, rodents | USA | Muscle pain, fever, headache, respiratory problems | + | Not documented | Phenoxymethylpenicillin | – | Parola and Raoult, | ||
| 9 | Meningitis | B | Humans, Cats, dogs | Worldwide spread | Sudden high fever, stiff neck, seizures, headache, nausea, vomiting, sleepiness | + | 10% | Penicillin G, ampicillin, chloramphenicol, cefotaxime, ceftriaxone | One polysaccharide vaccine (MPSV-4), two conjugate vaccines (MCV−4 | Pavri, | ||
| 10 | Japanese spotted fever | B | Rodents, Humans | Japan, South Korea | Acute high fever, Headache, exanthema | + | 2% | Doxycycline | No vaccine available | Ajesh et al., | ||
| 11 | Queensland tick typhus | B | Rodents, humans | Tasmania, Australia | Fever, muscle aches, chills, headache, and malaise | + | Not documented | Penicillin, doxycycline | No vaccine available | Carroll et al., | ||
| 12 | Mediterranean spotted fever/Boutonneuse fever | B | Dogs, rodents humans | Southern Europe, southern and western asia, Africa, India | Chills, high fevers, severe headache, muscular and articular pains, and photophobia | + | 2% | Tetracycline, along with chloramphenicol and quinolones | No vaccine available | Calisher et al., | ||
| 13 | Kenya tick typhus | B | Humans, dogs, rodents | Kenya | High fever, headache, chills, rash, muscle pain | + | 3% | Doxycycline, Chloramphenicol | No vaccine available | Dodd et al., | ||
| 14 | Indian tick typhus | B | Humans, dogs, rodents | India | High fever, headache, chills, rash, muscle pain | + | 1–5% | Doxycycline | No vaccine available | Muraleedharan, | ||
| 15 | Israeli tick typhus | B | Humans, dogs, rodents | Israel | High fever, headache, chills, rash, muscle pain | + | 1-5% | Doxycycline | No vaccine available | Muraleedharan, | ||
| 16 | Rocky Mountain spotted fever (RMSF) | B | Humans, rodents, dogs | North, Central and South America | Fever, headache, altered mental status, myalgia, and rash | + | 10–25% | Doxycycline, tetracycline | No vaccine available | Sarkar and Chatterjee, | ||
| 17 | Astrakhan spotted fever | B | Humans, rodents | North Caspian region of Russia | Fever, headache, altered mental status, myalgia, and rash | + | 1–5% | Doxycycline | No vaccine available | Muraleedharan, | ||
| 18 | Ehrlichiosis/Canine hemorrhagic fever | B | Dogs, humans | US-Southwest, Gulf coast regions | Fever, petechiae, vasculitis, lymphadenopathy, discharge from the nose and eyes, bleeding disorders, and edema of the legs and scrotum. | + | Not documented | Doxycycline, tetracycline | No vaccine available | Pattnaik, | ||
| 19 | African tick-bite fever | B | Humans, ruminants | Sub-Saharan Africa, West Indies | Fever, muscle ache, rash, swollen lymph nodes | + | 0% | Doxycycline, chloramphenicol, and ciprofloxacin | No vaccine available | Pai and HN, | ||
| 20 | American tick bite fever/ | B | Humans, rodents | North and South America | + | 0% | Doxycycline, chloramphenicol | Not yet available | Mourya and Yadav, | |||
| 21 | Dermacentor-borne necrosis erythema | B | Humans, rodents, lagomorphs | Asia, Europe | Fever, chills, rash | + | 0% | Doxycycline, tetracycline | No vaccine available | Muraleedharan, | ||
| 22 | North Asian tick typhus/siberian tick typhus | B | Rodents, humans | China, Russia, Mongolia | Rash, fever, skin ulcer at the site of tick bite, headache | + | 0% | Chloramphenicol, tetracycline | No vaccine available | Patil et al., | ||
| 23 | Lymphangitis-Associated Rickettsiosis | B | Rodents, humans | China, Southern France, Portugal, Africa | Rash, fever | + | 0% | Doxycycline | No vaccine available | Qattan et al., | ||
| 24 | Tick paralysis | – | Caused by toxin | Humans, dogs | USA, Australia | Weakness in legs that lead to paralysis | _ | 10-12% | Immediate tick removal | No vaccine available | Zaki, | |
| 25 | 364D rickettsiosis | B | Humans, jackrabbits, ground squirrels, and deer | California | Fever, malaise, and eschars | + | Not documented | Doxycycline | No vaccine available | Gritsun et al., | ||
| 26 | Colorado tick fever | V | Humans, elks, Marmots, deer | Colorado, Idaho, Canada | Fever, chills, headaches, pain, light sensitivity, muscle pain, rash, malaise | + | 0.5% | Analgesics and acetaminophen is used to relieve fever and pain, No proper treatment available | No vaccine available | Lin et al., | ||
| 27 | Powassan disease | V | Humans, squirrel, mice | Eastern Russia, North America | Fever, headache, nausea, weakness | + | 10% | No specific treatment is available | No vaccine available | Venugopal et al., | ||
| 28 | Tick-borne meningoencephalitis | V | Rodents, humans | Europe, Russia, Asia | Fever, anorexia, muscle aches, headache, malaise, nausea, and/or vomiting | + | European subtype F.R. = <2%. Far Eastern subtype F.R. = 20−40%, Siberian subtype F.R. = 2-3% | No specific treatment is available but corticosteroids can be used as an anti-inflammatory drugs | No vaccine available | Hollidge et al., | ||
| 29 | Crimean-Congo hemorrhagic fever | V | Humans,ruminants and ostriches | Northern Africa, Southern Europe, Southern part of Asia | Flu, vomiting, black stools, hemorrhage, nosebleeds | + | 10–40% | Ribavirin | Inactivated antigen CCHF vaccine | Villordo and Gamarnik, | ||
| 30 | Louping ill | V | Sheep, red grouse, humans | Scotland, America | Biphasic fever, depression, ataxia, posterior paralysis, muscular incoordination, tremors, coma, and death | + | 50–60% | No specific treatment is available | ATCvet | Singh and Gajadhar, | ||
| 31 | Kyasanur Forest Disease (KFD) | V | Rats, squirrels, mice, shrews, porcupines, humans | South Asia | High fever, hemorrhage, headache, bleeding from gums, nasal cavity throat, and gastro intestinal bleeding | + | 3–10% | No specific treatment is available | Formalin-inactivated KFDV | Walsh et al., | ||
| 32 | Alkhurma hemorrhagic fever (AHFV) | V | Camel, sheep | Saudi Arabia, Egypt | Non-specific flu-like symptoms, fever, anorexia, general malaise, diarrhea, vomiting, neurologic, and hemorrhagic symptoms | + | Above 30% | No specific treatment is available | No vaccine available | Charrel et al., | ||
| 33 | Heartland Virus Disease | V | White-tailed deer, raccoon | U.S. | Lethargy headaches, myalgia, loss of appetite, nausea, diarrhea, weight loss, arthralgia, leukopenia and thrombocytopenia | + | 12% | No specific treatment is available | No vaccine available | McMullan et al., | ||
| 34 | Bourbon virus disease | V | Unknown | Midwest and southern United States | Fever, tiredness, rash, headache, other body aches, nausea, and vomiting, thrombocytopenia and leukopenia | + | − | No specific treatment is available | No vaccine available | Devi, | ||
| 35 | Cytauxzoonosis | P | Bobcat, cougar | South east, South USA | Inappetance, lethargy, high fever, respiratory distress, tachycardia | – | Without treatment = 97%, with treatment = 40% | Imidocarb dipropionate and a combination of azithromycin and atovaquone | No vaccine available | Singh et al., | ||
| 36 | Babesiosis | P | Rodents, humans | US-Northeast, West coast | Fever, chills, sweats, nausea, or fatigue headache, body aches, loss of appetite | + | 42% | Combination of clindamycin, doxycycline, and azithromycin | No vaccine available | de la Fuente et al., |
Figure 1Map indicating states (colored in orange) in India and the regions (labeled in red) where Kyasanur Forest Disease has been reported.
Figure 2Molecular phylogenetic analysis by Maximum Likelihood method. The evolutionary history was inferred by using the Maximum Likelihood method based on the Tamura-Nei model. The tree with the highest log likelihood is shown. Alkumra hemorrhagic fever virus can be seen as the most closely related neighbor to KFD in the phylogenetic tree.
Figure 3The confluence of factors responsible for Kyasanur Forest disease (KFD). All of these factors when present in right proportions result in an optimum season for the development of KFD.
Figure 4Transmission of Kyasanur Forest Disease Virus (KFDV). From tick larva and nymph, transmission to primary hosts- small mammals and monkeys- occur and afterwards to humans who experience contact with dead animal of infected tick bite. Infected adult tick can directly transmit the virus to humans and large animals. Transmission from infected large animals is limited while human-human transmission has not yet been reported. People inhabiting forests are more likely to be infected with KFDV.
Figure 5Proposed pathogenesis model of Kyasanur Forest Disease. Virus enters (1) in body on tick bite or through contact with an infected animal. Virus initially targets macrophages and dendritic cells. Multiplication of virus (2) in these host cells yields high viremia, leading to systemic spread of the virus to spleen, liver, and other replication sites to produce disease symptoms. The infected antigen presenting cells (APCs), that present viral antigens to T cells, could release large amounts of pro-inflammatory cytokines early after infection and also modulate host immune response (3) via type 1 interferon production. Antigen positive (activated) T cells could also produce IFN-1. Subsequent activation of the JAK-STAT signaling induces an antiviral state for alleviating virus burden. Humoral immune response via production of antibodies by activated B cells might also assist in viral clearance from the body. To counter the host immune response, KFDV employs its NS5 non-structural protein to antagonize IFN response (4) by inhibiting JAK-STAT pathway, possibly bringing about uncontrolled viral replication and poor immune response. The multi-systemic illness might be attributed to the pro-inflammatory cytokine storm that could contribute to immunosuppression and disease progression (5) by inducing disseminated intravascular coagulation (DIC), neurological complications and vascular dysfunction that leads to hemorrhagic manifestations, multi-organ failure and shock. These complications altogether finally result in death.